{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:11:44Z","timestamp":1793052704419,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>DNA methylation inhibitors (azacitidine, decitabine) have revolutionized the treatment dilemma of myelodysplastic syndromes (MDS), a group of malignant hematopoietic disorders. This study evaluates the adverse drug reactions (ADRs) following the use of DNA methylation inhibitors in the World Health Organization (WHO) VigiAccess database and compares the characteristics of ADRs between the two drugs to select the drug with the minimum individualized risk for patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study employed a retrospective descriptive analysis method. We compiled ADR reports for two marketed DNA methylation inhibitors for the treatment of MDS from WHO-VigiAccess. Data collected included demographic data such as age groups, gender, and regions of global patients covered by ADR reports, as well as data on the disease systems and symptoms caused by ADRs recorded in the annual reports and reports received by WHO. By calculating the proportion of ADRs reported for each drug, we compared the similarities and differences in ADRs between the two drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 23,763 adverse events (AEs) related to the two DNA methylation inhibitors were reported in VigiAccess. The results showed that the top 10 most common AEs were febrile neutropenia, bone marrow suppression, neutropenia, anemia, pancytopenia, leukopenia, thrombocytopenia, bone marrow failure, agranulocytosis, and hematotoxicity. The top five common types of DNA methylation inhibitor AEs were blood and lymphatic system disorders (11,178 cases, 47.0%), cardiac organ diseases (1,488 cases, 6.3%), various congenital familial genetic diseases (49 cases, 0.2%), ear and labyrinth diseases (100, 4.2%), and endocrine system diseases (57, 2.4%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is no Strong correlation between DNA methylation inhibitors and ADRs. Current comparative observational studies of these inhibitors show that there are common and specific adverse reactions in the ADR reports received by WHO for these drugs. Clinicians should improve the rational use of these drugs based on the characteristics of ADRs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1470148","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T04:52:13Z","timestamp":1727844733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess"],"prefix":"10.3389","volume":"15","author":[{"given":"Qiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanlei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","article-title":"Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase\u00ae","volume":"39","author":"Ampadu","year":"2016","journal-title":"Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14740338.2019.1630063","article-title":"Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseases","volume":"18","author":"Chen","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3390\/genes12081144","article-title":"The genetics of myelodysplastic syndromes: clinical relevance","volume":"12","author":"Chiereghin","year":"2021","journal-title":"Genes (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"B5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/leu.2008.397","article-title":"The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells","volume":"23","author":"Flotho","year":"2009","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.biochi.2012.07.025","article-title":"DNA methylation inhibitors in cancer: recent and future approaches","volume":"94","author":"Gros","year":"2012","journal-title":"Biochimie"},{"key":"B9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.leukres.2014.11.009","article-title":"Azacitidine for the treatment of relapsed and refractory AML in older patients","volume":"39","author":"Itzykson","year":"2015","journal-title":"Leukemia Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","article-title":"Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes","volume":"11","author":"Kaminskas","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/bjh.12256","article-title":"Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes","volume":"161","author":"Lee","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","article-title":"A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database","volume":"23","author":"Lindquist","year":"2000","journal-title":"Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.1016\/j.clml.2021.01.024","article-title":"Comparison of azacitidine and decitabine in myelodysplastic syndromes and acute myeloid leukemia: a network meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa2119771","article-title":"Demethylation and up-regulation of an oncogene after hypomethylating therapy","volume":"386","author":"Liu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ajh.23368","article-title":"Predicting infections in high-risk patients with myelodysplastic syndrome\/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study","volume":"88","author":"Merkel","year":"2013","journal-title":"Am. J. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1182\/blood.v124.21.5622.5622","article-title":"Infections in patients with myelodysplastic syndrome\/acute myeloid leukemia treated with azacitidine: report from a single center","volume":"124","author":"Quinto","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"Jama"},{"key":"B20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2020.00315","article-title":"Intravitreal anti-VEGF drugs and signals of dementia and Parkinson-like events: analysis of the VigiBase database of spontaneous reports","volume":"11","author":"Sultana","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase\u00ae","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2109365","DOI":"10.1080\/21645515.2022.2109365","article-title":"Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: a descriptive analysis from VigiAccess","volume":"18","author":"Yamoah","year":"2022","journal-title":"Hum. Vaccin Immunother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1470148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T04:52:14Z","timestamp":1727844734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1470148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":22,"alternative-id":["10.3389\/fphar.2024.1470148"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1470148","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"article-number":"1470148"}}